DUBLIN – Synox Therapeutics Ltd., a spin-out from Celleron Therapeutics Ltd., has raised €37 million (US$43.7 million) in a series A round to conduct a pivotal trial of emactuzumab, an antibody its parent company in-licensed from Roche Holding AG in August.
DUBLIN – Health care investor Syncona Ltd. has founded a new startup, Purespring Therapeutics Ltd., to take gene therapy into the kidney. It is committing £45 million (US$59.6 million) in series A funding, which will support the build-out of the new company and take at least one program into the clinic.
Biopharmas raising money in public or private financings, including: 4D Molecular, Beyondspring, Briacell, Elevation, Emergex, Evommune, Five Prime, Gan & Lee, Hemogenyx, Keros, Kodiak, Oblique, Oncternal, Oric, Pharvaris, Population Health Investment, Qiming, Scopus, Umoja, Xiaomi.
Olema Pharmaceuticals Inc., a company looking to improve on current endocrine therapies with an oral estrogen receptor antagonist and degrader of its own, has filed for a $170 million IPO on Nasdaq. The offering follows an $87.4 million series C round, closed in September and a $54 million series B financing closed not long before in July.
Biopharmas raising money in public or private financings, including: Bioatla, Compass, Intervenn, Kinnate, Moberg, Nereid, Oncozenge, Sigilon, Stat Codon.
HONG KONG – Kira Pharmaceuticals is riding high after completing a $46 million fundraiser and appointing Frederick Beddingfield as CEO. “The $46 million comprises a series A of $18 million and a series B of $26 million, with investors Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital participating in both rounds,” Beddingfield told BioWorld.
LONDON – Synendos Therapeutics AG is poised for a fresh attempt at drugging the endogenous endocannabinoid system after raising CHF20 million (US$21.8 million) to take its lead program into clinical development.
RSS
